News | November 04, 2024
Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Aims to achieve CDMO sales of US$ 400 million by 2028
He holds a Master’s in Management from the National University of Singapore
India Business grew by 11.9% YoY to Rs. 1196.2 crore
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Our centers are performing as expected or even better
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
